AP2715A - Use of imatinib to treat liver disorders and viralinfections - Google Patents

Use of imatinib to treat liver disorders and viralinfections

Info

Publication number
AP2715A
AP2715A AP2006003863A AP2006003863A AP2715A AP 2715 A AP2715 A AP 2715A AP 2006003863 A AP2006003863 A AP 2006003863A AP 2006003863 A AP2006003863 A AP 2006003863A AP 2715 A AP2715 A AP 2715A
Authority
AP
ARIPO
Prior art keywords
viralinfections
imatinib
liver disorders
treat liver
treat
Prior art date
Application number
AP2006003863A
Other languages
English (en)
Other versions
AP2006003863A0 (en
Inventor
Phillipe Riviere
Marc Riviere
Stephanie Reader
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35462722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2715(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Publication of AP2006003863A0 publication Critical patent/AP2006003863A0/xx
Application granted granted Critical
Publication of AP2715A publication Critical patent/AP2715A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AP2006003863A 2004-06-04 2005-06-03 Use of imatinib to treat liver disorders and viralinfections AP2715A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57657304P 2004-06-04 2004-06-04
PCT/CA2005/000869 WO2005117885A1 (en) 2004-06-04 2005-06-03 Use of imatinib to treat liver disorders and viral infections

Publications (2)

Publication Number Publication Date
AP2006003863A0 AP2006003863A0 (en) 2006-12-31
AP2715A true AP2715A (en) 2013-07-31

Family

ID=35462722

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003863A AP2715A (en) 2004-06-04 2005-06-03 Use of imatinib to treat liver disorders and viralinfections

Country Status (25)

Country Link
US (1) US8293745B2 (ru)
EP (1) EP1750713B1 (ru)
JP (1) JP5015769B2 (ru)
KR (1) KR101246863B1 (ru)
CN (2) CN102085202A (ru)
AP (1) AP2715A (ru)
AR (1) AR049141A1 (ru)
AU (1) AU2005249159A1 (ru)
BR (1) BRPI0511805A (ru)
CA (1) CA2568671A1 (ru)
DK (1) DK1750713T3 (ru)
EA (1) EA013813B1 (ru)
EC (1) ECSP055833A (ru)
ES (1) ES2397830T3 (ru)
IL (1) IL179796A0 (ru)
MA (1) MA28840B1 (ru)
MX (1) MXPA06014063A (ru)
MY (1) MY148676A (ru)
PE (1) PE20060399A1 (ru)
PL (1) PL1750713T3 (ru)
PT (1) PT1750713E (ru)
TN (1) TNSN06398A1 (ru)
TW (1) TWI393565B (ru)
UY (1) UY28942A1 (ru)
WO (1) WO2005117885A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5520433B2 (ja) * 2004-01-21 2014-06-11 エモリー ユニバーシティー 病原体感染を処置するためのチロシンキナーゼインヒビターの組成物および使用
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
CN102351842B (zh) 2005-11-25 2014-07-23 诺华股份有限公司 甲磺酸伊马替尼的f、g、h、i 和k晶形
WO2007097149A1 (ja) 2006-02-20 2007-08-30 Konica Minolta Holdings, Inc. 有機エレクトロルミネッセンス素子、白色発光素子、表示装置、及び照明装置
US9987277B2 (en) 2006-10-04 2018-06-05 Janssen Sciences Ireland Uc Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C
WO2009021150A2 (en) * 2007-08-08 2009-02-12 California Pacific Medical Center Platelet derived growth factor receptor supports cytomegalovirus infectivity
FR2923160B1 (fr) * 2007-11-02 2013-07-26 Pasteur Institut Composes destines a prevenir ou traiter une infection virale.
US8759010B2 (en) 2008-09-26 2014-06-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Host cell kinases as targets for antiviral therapies against HCV infection
US20110236349A1 (en) * 2008-12-19 2011-09-29 Koff Jonathan L Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection
WO2012118599A1 (en) * 2011-02-28 2012-09-07 Emory University C-abl tyrosine kinase inhibitors useful for inhibiting filovirus replication
WO2013024158A1 (en) * 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
KR101386697B1 (ko) 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
AU2013326850B2 (en) * 2012-10-04 2017-09-21 Inhibikase Therapeutics, Inc. Novel compounds, their preparation and their uses
WO2017083971A1 (en) * 2015-11-16 2017-05-26 University Of Manitoba Compositions and methods for treatment of influenza
CN111481671A (zh) * 2020-05-26 2020-08-04 华中科技大学同济医学院附属协和医院 酪氨酸激酶抑制剂在制备系统性红斑狼疮脑病药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072826A2 (en) * 2004-01-21 2005-08-11 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1018558A3 (en) * 1990-04-06 2002-06-05 Genelabs Technologies, Inc. Hepatitis C Virus Epitopes
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US20030191048A1 (en) * 2000-08-01 2003-10-09 Mattias Luukkonen Gene expression profile for KSHV infection and methods for treating same
US6884804B2 (en) 2001-05-16 2005-04-26 Vertex Pharmaceuticals Incorporated Inhibitors of Src and other protein kinases
US20050176687A1 (en) * 2001-06-29 2005-08-11 Alain Moussy Use of tyrosine kinase inhibitors for treating autoimmune diseases
GB2398781B (en) * 2002-05-23 2005-02-02 Cytopia Pty Ltd Kinase inhibitors
US7064127B2 (en) * 2003-12-19 2006-06-20 Mount Sinai School Of Medicine Of New York University Treatment of hepatic fibrosis with imatinib mesylate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072826A2 (en) * 2004-01-21 2005-08-11 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Anti-Cancer Drugs, Apr. 2004, vol. 15 (4), pp. 405-409 (RAMADORE ET AL.) "Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis", whole document *
Haematologica, 2002, vol. 87 (11), pp. 1200-1208 (SILINI ET AL.) "Hepatitis C virus infection in a hematology ward: evidence for nosocomial transmission and impact on hematologic disease outcome", whole document *
Trends in Biotechnology, 2003, vol. 21 (10), pp. 452-457 (DEFILIPPIS ET AL.) "Functional genomics in virology and antiviral drug discovery", whole document *

Also Published As

Publication number Publication date
UY28942A1 (es) 2005-11-30
PE20060399A1 (es) 2006-07-06
IL179796A0 (en) 2007-05-15
KR20070051832A (ko) 2007-05-18
PT1750713E (pt) 2013-01-25
EA013813B1 (ru) 2010-08-30
EP1750713B1 (en) 2012-10-17
MA28840B1 (fr) 2007-09-03
JP2008501646A (ja) 2008-01-24
AP2006003863A0 (en) 2006-12-31
ES2397830T3 (es) 2013-03-11
EA200602289A1 (ru) 2007-04-27
TWI393565B (zh) 2013-04-21
MXPA06014063A (es) 2007-04-25
BRPI0511805A (pt) 2008-01-15
EP1750713A1 (en) 2007-02-14
WO2005117885A1 (en) 2005-12-15
DK1750713T3 (da) 2013-02-11
AU2005249159A1 (en) 2005-12-15
KR101246863B1 (ko) 2013-03-25
ECSP055833A (es) 2005-09-20
CA2568671A1 (en) 2005-12-15
US20060275260A1 (en) 2006-12-07
EP1750713A4 (en) 2010-09-15
CN102085202A (zh) 2011-06-08
JP5015769B2 (ja) 2012-08-29
TNSN06398A1 (en) 2008-02-22
US8293745B2 (en) 2012-10-23
TW200602059A (en) 2006-01-16
MY148676A (en) 2013-05-31
CN1976709A (zh) 2007-06-06
AR049141A1 (es) 2006-06-28
PL1750713T3 (pl) 2013-04-30

Similar Documents

Publication Publication Date Title
AP2715A (en) Use of imatinib to treat liver disorders and viralinfections
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
HK1126212A1 (en) Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EP1874286A4 (en) METHOD AND COMPOSITIONS FOR TREATING ANXIETY STATE
SI1791791T1 (sl) Postopki in sestavki za obdelavo vode
IL177772A0 (en) Methods and compositions for the treatment of gastrointestinal disorders
ZA200806114B (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
HK1116660A1 (en) Use of bmp antagonists to regulate hepcidin-mediated iron metabolism and treat iron deficiency bmp
IL176958A0 (en) Compounds and methods of use
HK1112241A1 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
IL180251A0 (en) Methods and reagents for the treatment of metabolic disorders
EP1831207A4 (en) AMINO-PRIMIDINE COMPOUNDS AND METHOD OF USE
IL189364A0 (en) Estrogen compositions and therapeutic methods of use thereof
IL178996A0 (en) Thienopyridinone compounds and methods of treatment
EP1786265A4 (en) NEW COMPOSITIONS AND PROCESSING METHODS
IL182436A0 (en) Thienopyridinone compounds and methods of treatment
IL189009A0 (en) Methods and compositions for the treatment of neuropathies and related disorders
EP1812451A4 (en) COMPOUNDS AND METHODS OF USE THEREOF
HK1109576A1 (en) Aequorin-containing compositions and methods of using same
EP1765331A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY DISEASES
IL178970A0 (en) Haplotype markers and methods of using the same to determine response to treatment
ZA200700749B (en) Methods and reagents for the treatment of metabolic disorders
EP1755581A4 (en) METHODS AND COMPOSITIONS FOR TREATING MYOCARDIAL CONDITIONS
PT2227246E (pt) Tratamento de fibroses e distúrbios hepáticos
GB0504657D0 (en) Compositions and methods of treatment